CAR-TCR Summit Europe 2021 | Targetting cancer with allogeneic NK cell therapies

James Trager, PhD, NKarta Therapeutics, South San Francisco, CA, provides an overview of his presentation at the CAR-TCR Summit Europe 2021 on the use of engineered natural killer (NK) cells for allogeneic therapy and describes NKX019, an allogeneic CD19-directed chimeric antigen receptor (CAR)-engineered NK cell, which is being studied preclinically in B cell malignancies. CAR-NK cells have been demonstrated to posses a greater inherent cytotoxicity and reduced risk of cytokine release syndrome compared to CAR-T cells. He also introduces a novel strategy currently under preclinical investigation which involves combining NK and T-cell modalities due to their synergistic properties. This interview took place during the CAR-TCR Summit Europe 2021.